Does Modulating the Gut Hormones, Incretins, Modify Vascular Function, Thereby Reducing the Risk of Vascular Complications in Insulin Resistant Individuals?
Phase of Trial: Phase III
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Insulin resistance
- Focus Pharmacodynamics
- 24 Apr 2017 Status changed from recruiting to completed.
- 17 May 2010 New trial record